Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 ‘201’ Clinical Trial of IkT-148009 to Treat Parkinson’s Disease
BOSTON and ATLANTA, May 16, 2023 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that the first patient has been dosed in its Phase 2 ‘201’ trial evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, … Read more